Compare JetBlue Airways Corporation (JBLU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? JetBlue Airways Corporation trades at $3.84 (market cap $1.48B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 86.2× JetBlue Airways Corporation's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| JBLU | VRTX | |
|---|---|---|
Market Cap | $1.48B | $127.55B |
Volume | 30,275,693 | 1,487,944 |
Sector | Industrials | Health |
52-Week High | $6.46 | $557.96 |
52-Week Low | $3.84 | $407.37 |
Typical Hold Time | 44 Days | 120 Days |
Enterprise Value | $8.84B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.92, down 1.26% today, reflecting ongoing operational challenges. The airline faces persistent profitability issues with a net income margin of -9.32% and negative ROE of -44.36%. Recent Q2 2026 earnings beat expectations but followed two consecutive misses. Technical indicators show bearish momentum with the stock trading near key support levels. The company continues expansion efforts with new Colombia routes while grappling with high fuel costs and capacity constraints.
Investment outlook remains cautious given sustained losses and high debt levels. The consensus price target of $5.89 offers 50% upside potential, but execution risks from fuel price volatility and competitive pressures persist. Analyst sentiment leans neutral with 62% hold ratings, suggesting limited near-term catalysts for significant price appreciation despite attractive valuation multiples.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, with a bearish technical signal despite strong fundamentals. The company maintains dominant cystic fibrosis market position with 86% gross margins and 35% net income margin. Recent positive Phase 2b data for inaxaplin in kidney disease shows pipeline expansion potential. Revenue grew to $12.0B in 2025 with $3.95B net income, recovering from 2024's loss.
Analyst consensus remains strongly bullish with 84% buy ratings and $573.50 price target, representing 14% upside. Key risks include pipeline execution and competitive pressures. The stock offers growth potential through gene therapy expansion but faces volatility from clinical trial outcomes and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
